Greater Cannabis Company (GCAN) Amortizatization of Intangibles (2017 - 2022)
Greater Cannabis Company's (GCAN) quarterly Amortizatization of Intangibles came in at $98342.0 in Q1 2022, up 714.22% year-on-year from $12078.0 in Q1 2021, and up 39.81% quarter-over-quarter from $70339.0 in Q4 2021.
Greater Cannabis Company (GCAN) Amortizatization of Intangibles (2017 - 2022) Analysis & Trends
Greater Cannabis Company's Amortizatization of Intangibles history runs 6 years deep, the most recent figure standing at $98342.0 for Q1 2022.
- On a quarterly basis, Amortizatization of Intangibles rose 714.22% year-over-year to $98342.0 in Q1 2022; TTM through Dec 2022 was $98342.0, a 63.42% decrease from a year earlier, with the FY2022 full-year figure at $98342.0, down 63.42% from the prior year.
- Amortizatization of Intangibles rose to $98342.0 in Q1 2022 per GCAN's latest filing, from $70339.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $394800.0 in Q2 2020 and bottomed at $4986.0 in Q4 2018.
- The 5-year median for Amortizatization of Intangibles is $68691.0 (2021), against an average of $112640.6.
- Across the five-year window, Amortizatization of Intangibles soared 5764.52% in 2019 and slumped 95.93% in 2021, its largest moves.
- Year by year, Amortizatization of Intangibles stood at $4986.0 in 2018, then surged by 5764.52% to $292405.0 in 2019, then slumped by 50.26% to $145450.0 in 2020, then plunged by 51.64% to $70339.0 in 2021, then surged by 39.81% to $98342.0 in 2022.
- Per Business Quant, the three latest GCAN Amortizatization of Intangibles figures stand at $98342.0 (Q1 2022), $70339.0 (Q4 2021), and $117746.0 (Q3 2021).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.30 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Greater Cannabis Company | 236,233.75 | 234,794.75 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 98,342.00 |
| Mar 31, 2022 | 98,342.00 |
| Dec 31, 2021 | 70,339.00 |
| Dec 31, 2021 | 70,339.00 |
| Sep 30, 2021 | 117,746.00 |
| Sep 30, 2021 | 117,746.00 |
| Jun 30, 2021 | 68,691.00 |
| Jun 30, 2021 | 68,691.00 |
| Mar 31, 2021 | 12,078.00 |
| Mar 31, 2021 | 12,078.00 |
| Dec 31, 2020 | 145,450.00 |
| Dec 31, 2020 | 145,450.00 |
| Sep 30, 2020 | 178,280.00 |
| Sep 30, 2020 | 178,280.00 |
| Jun 30, 2020 | 394,800.00 |
| Jun 30, 2020 | 394,800.00 |
| Mar 31, 2020 | 297,073.00 |
| Mar 31, 2020 | 297,073.00 |
| Dec 31, 2019 | 292,405.00 |
| Dec 31, 2019 | 292,405.00 |